Joseph Daley, MD
Pulmonary Disease · Cape Coral, FLNPI 1578552907
Payments from drug & device makers
What this record shows
This record is dominated by education: $7,029 of the $9,666 with a category attached, or 72.7%. Intuitive Surgical accounts for 82.3% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $8,143 and has fallen 97.8% since, to $181 in 2025.
Across 99 payments — averaging $97.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- GSK$505
- AstraZeneca$428
- Boehringer Ingelheim$167
- Grifols USA, LLC$134
- Inspire Medical Systems, Inc.$88
- plus $393 from 12 others
What the payments were for
- Travel & lodging$93410%
- Food & beverage$1,70218%
- Education$7,02973%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $7,951 |
| GSK | 35 | $505 |
| AstraZeneca | 17 | $428 |
| Boehringer Ingelheim | 7 | $167 |
| Grifols USA, LLC | 6 | $134 |
| Inspire Medical Systems, Inc. | 4 | $88 |
| Insmed, Inc. | 4 | $73 |
| Mylan Specialty L.p. | 3 | $68 |
| Shire North American Group Inc | 3 | $65 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Boston Scientific | 1 | $27 |
| Sanofi | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Advanced Respiratory, Inc | 1 | $20 |
| Electromed, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,909
- TAGRISSO$125
- NUCALA$102
How this compares
$9,666 in reported general payments places this provider in the 75th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 431 | $345,932 |
| Breo ElliptaFluticasone/Vilanterol | 246 | $156,240 |
| OfevNintedanib Esylate | 11 | $141,409 |
| Spiriva RespimatTiotropium Bromide | 89 | $74,264 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 122 | $67,163 |
| NucalaMepolizumab | 15 | $64,203 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 57 | $45,990 |
| Spiriva HandihalerTiotropium Bromide | 48 | $44,438 |
| EliquisApixaban | 53 | $35,322 |
| SymbicortBudesonide/Formoterol Fumarate | 100 | $34,703 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 53 | $34,369 |
| Arnuity ElliptaFluticasone Furoate | 102 | $32,621 |
| Incruse ElliptaUmeclidinium Bromide | 65 | $26,410 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 648 | $17,716 |
| BreynaBudesonide/Formoterol Fumarate | 52 | $15,532 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Arnuity Ellipta | $505 | $692,570981 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $167 | $250,041153 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $428 | $80,693157 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Cape Coral
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.